Cytomel (Liothyronine): How to Safely Stop Taking T3

What Is Liothyronine and How Does It Work?

Liothyronine is the synthetic form of triiodothyronine (T3), the metabolically active thyroid hormone. Unlike levothyroxine (T4), which must be converted to T3 in peripheral tissues by deiodinase enzymes, liothyronine acts directly on nuclear thyroid hormone receptors throughout the body. This makes its onset of action fast (within hours) and its offset equally fast once dosing stops.

Receptor Binding and Cellular Mechanism

T3 binds thyroid hormone receptor alpha (TR-alpha) and thyroid hormone receptor beta (TR-beta) with roughly 10 to 15 times greater affinity than T4 [1]. Once bound, the receptor complex enters the cell nucleus and modulates transcription of genes controlling basal metabolic rate, heart rate, gut motility, and cognitive function. Because liothyronine skips the deiodinase conversion step entirely, patients with impaired type 2 deiodinase activity (a common single-nucleotide polymorphism affecting roughly 12 to 16% of the population) may absorb more clinical benefit from it than from levothyroxine alone [2].

Why the Short Half-Life Matters for Stopping

Liothyronine has a plasma half-life of approximately 19 hours in euthyroid individuals, compared to 6 to 7 days for levothyroxine [3]. This pharmacokinetic difference has two practical consequences for discontinuation. First, serum free T3 levels fall measurably within 24 to 48 hours of the last dose. Second, the hypothalamic-pituitary axis, which was partially suppressed by exogenous T3, needs days to weeks to re-establish normal TSH pulsatility. Stopping abruptly collapses T3 levels faster than TSH can rise, leaving a symptomatic gap.

Approved Indications

The FDA labels liothyronine for hypothyroidism, myxedema coma, and as a diagnostic agent during thyroid suppression testing [4]. Off-label uses include adjunctive treatment of treatment-resistant depression, combination therapy with levothyroxine for persistent hypothyroid symptoms, and short-term use before radioiodine scanning.

Why You Cannot Simply Stop Liothyronine Cold Turkey

Abrupt discontinuation of liothyronine exposes patients to two overlapping problems: a rapid drop in circulating T3 (because of the short half-life) and a delayed TSH recovery (because pituitary thyrotrophs remain partially suppressed for 2 to 6 weeks after the last dose). The combined effect is a window of functional hypothyroidism that can last 3 to 8 weeks even in patients with intact thyroid glands.

The TSH Recovery Lag

After stopping exogenous thyroid hormone, TSH does not normalize immediately. Research published in the Journal of Clinical Endocrinology and Metabolism shows that pituitary TSH suppression from exogenous thyroid hormone can persist for 4 to 6 weeks after cessation, with full hypothalamic-pituitary-thyroid axis recovery requiring up to 3 months in some cases [5]. During this window, even a patient whose thyroid gland is structurally intact may produce insufficient endogenous T3 and T4 to keep them symptom-free.

Symptoms of Abrupt Withdrawal

Symptoms that appear within 48 to 96 hours of stopping liothyronine include:

• Fatigue and general malaise
• Cold intolerance
• Cognitive slowing and difficulty concentrating
• Constipation and slowed gut motility
• Mild weight gain from reduced metabolic rate
• Depression and low mood
• Bradycardia (resting heart rate drop of 5 to 10 bpm in some patients)

These symptoms are not unique to liothyronine withdrawal. They overlap significantly with de-novo hypothyroidism and with several other conditions, which is why labs are mandatory rather than optional during a taper.

Who Is at Highest Risk

Patients on liothyronine for more than 6 months, those on doses above 25 mcg/day, and individuals with autoimmune thyroiditis (Hashimoto's disease) who have little residual thyroid function are most vulnerable to symptomatic withdrawal. A 2019 analysis in the European Journal of Endocrinology found that patients on combination T4/T3 therapy who abruptly reverted to T4 monotherapy reported significantly higher symptom burden scores during the first 4 weeks compared to those who tapered over 6 weeks [6].

The Standard Liothyronine Taper Protocol

The standard approach is a stepwise 25% to 50% dose reduction every 1 to 2 weeks, with baseline labs drawn before the first reduction. The total taper duration depends on the starting dose and the duration of prior use.

Baseline Labs Before You Start

Draw the following before reducing the first dose:

• TSH (thyrotropin)
• Free T3
• Free T4
• If switching to levothyroxine: confirm the target T4 dose with your prescriber before day one

Taper Schedule by Starting Dose

Starting dose 5 mcg/day: Reduce to 2.5 mcg/day for 2 weeks, then stop. Total taper: 2 weeks.

Starting dose 25 mcg/day: Reduce to 12.5 mcg/day for 2 weeks, then to 5 mcg/day for 2 weeks, then stop. Total taper: 4 weeks.

Starting dose 50 mcg/day: Reduce to 37.5 mcg/day for 2 weeks, then to 25 mcg/day for 2 weeks, then to 12.5 mcg/day for 2 weeks, then stop. Total taper: 6 weeks.

Starting dose above 75 mcg/day (uncommon, often seen post-thyroidectomy or in thyroid cancer suppression): A 12-week taper with a reduction of approximately 12.5 to 25 mcg every 2 weeks is reasonable. Oncology-specific protocols differ and should be guided by the treating endocrinologist.

Monitoring During the Taper

Check TSH and free T4 at week 4 of the taper and again 4 to 6 weeks after the final dose. Free T3 normalizes quickly once endogenous production resumes, so it is less informative than TSH and free T4 during recovery. If TSH rises above 10 mIU/L at any point during the taper and the patient is symptomatic, the taper should pause or the dose should be held at the current level until TSH stabilizes.

Switching From Liothyronine to Levothyroxine Monotherapy

Many patients on combination T3/T4 therapy or on liothyronine monotherapy are switched to levothyroxine monotherapy, which is the standard of care per the American Thyroid Association 2014 guidelines [7]. The transition is not simply stopping one drug and starting another. Done correctly, it involves overlapping the medications.

How to Overlap

Start levothyroxine on the same day as the first liothyronine dose reduction. The approximate conversion is that 25 mcg of liothyronine is biologically equivalent to roughly 75 to 100 mcg of levothyroxine [8]. This ratio is approximate and individual variation is substantial, so most prescribers start levothyroxine at a conservative dose (e.g., 50 to 75 mcg/day) and uptitrate based on TSH at 6 to 8 weeks.

Why the ATA Recommends T4 Monotherapy as Default

The American Thyroid Association's clinical practice guidelines state: "We recommend against the routine use of combination T4 and T3 therapy in patients with hypothyroidism" based on the finding that most patients achieve adequate tissue T3 levels through peripheral conversion of T4 [7]. The Bunevicius et al. Crossover trial published in the New England Journal of Medicine (N=33) showed mood and cognitive improvements in some patients on combination T4/T3 therapy compared to T4 alone [9], but larger subsequent trials have not consistently replicated this finding across general hypothyroid populations [10].

What to Expect During Transition

Patients often feel worse during weeks 1 through 3 of the switch, even when the transition is done correctly, because levothyroxine takes 4 to 6 weeks to reach steady state. Setting this expectation in advance prevents unnecessary dose adjustments or early abandonment of the new regimen.

Special Situations: Radioiodine Therapy and Thyroid Cancer Surveillance

Patients scheduled for I-131 radioiodine therapy or a diagnostic whole-body scan must stop all thyroid hormone to allow TSH to rise above 25 to 30 mIU/L, which is necessary for adequate radioiodine uptake. The protocol differs depending on what the patient is taking.

Stopping Liothyronine Before Radioiodine

The FDA-approved protocol and the American Thyroid Association guidelines specify stopping liothyronine 14 days before radioiodine therapy or diagnostic scanning [7, 4]. Because of the short half-life, 14 days is sufficient for liothyronine to clear and TSH to rise. Patients on levothyroxine require a 4-week withdrawal, since the longer half-life means the drug takes roughly 5 weeks to drop to near-zero.

Recombinant TSH as an Alternative

Recombinant human TSH (rhTSH, brand name Thyrogen) injections (0.9 mg IM on days 1 and 2, scan or ablation on day 3 or 5) allow thyroid cancer surveillance without stopping thyroid hormone entirely [11]. This approach is preferred for patients in whom hypothyroid withdrawal poses significant risk, such as those with cardiac disease, psychiatric illness, or severe baseline symptoms. The FDA approved rhTSH for use in well-differentiated thyroid cancer surveillance and low-risk ablation [11].

Liothyronine and Depression: What Happens When You Stop

Liothyronine at doses of 25 to 50 mcg/day has been used as an augmentation strategy in treatment-resistant unipolar depression, often added to antidepressants when adequate response has not been achieved. The American Psychiatric Association practice guidelines acknowledge T3 augmentation as a second-line option in this context [12]. Stopping it in psychiatric patients requires coordination between the prescribing psychiatrist and an endocrinologist.

Risk of Mood Relapse

Patients who responded to liothyronine augmentation for depression may experience mood deterioration during and after the taper. This is not purely a pharmacological effect. Hypothyroid symptoms overlap substantially with depressive symptoms, and the distinction between thyroid withdrawal and psychiatric relapse can be clinically difficult. A TSH drawn at the time of mood deterioration is the fastest way to distinguish them.

Recommended Taper in Psychiatric Patients

Reduce by no more than 12.5 mcg per week in psychiatric patients on liothyronine for depression augmentation. Weekly contact with the prescribing clinician during the taper is advisable. If depressive symptoms worsen significantly at any taper step, pause the reduction and reassess. Do not drop two dose levels simultaneously to speed the process.

Labs, Timelines, and Criteria for Restarting

Knowing when to restart liothyronine (or levothyroxine) after a planned discontinuation is as important as knowing how to stop. The restart decision is laboratory-driven, not symptom-driven alone.

When to Restart

| Scenario | Restart Threshold | |---|---| | Primary hypothyroidism, non-pregnant | TSH >10 mIU/L with symptoms, or TSH >20 mIU/L regardless of symptoms | | Pregnancy or planning pregnancy | TSH >2.5 mIU/L in first trimester, >3.0 mIU/L in second and third trimester [13] | | Subclinical hypothyroidism post-taper | TSH 4.5 to 10 mIU/L: monitor; treat if symptomatic or TSH rising | | Post-thyroidectomy for cancer | TSH must remain suppressed; restart immediately after scan per oncology protocol |

Lab Draw Timing After the Final Dose

• Week 2: optional free T3 if symptoms are severe
• Week 4: TSH and free T4 (most informative time point)
• Week 8: confirmatory TSH and free T4
• Week 12: if TSH is still suppressed at week 8 (rare), recheck at 12 weeks before concluding the axis has recovered

A TSH that remains suppressed (below 0.5 mIU/L) 8 weeks after the last dose raises the possibility of exogenous thyroid hormone exposure not disclosed to the prescriber, a TSH-secreting pituitary adenoma, or Graves' disease that was masked by the medication.

Practical Patient Instructions for the Day of the Last Dose

On the day you take your last liothyronine tablet, do the following:

1. Write down the date and your final dose in a medication log.
2. Confirm your 4-week lab appointment is already scheduled.
3. Have a written list of hypothyroid symptoms to track weekly: energy, cold tolerance, bowel frequency, resting heart rate, weight, and mood.
4. Avoid starting any new herbal supplements marketed for "thyroid support" during the taper. Products containing bladderwrack, kelp, or desiccated thyroid glandulars introduce unquantified amounts of iodine and thyroid hormone that complicate TSH interpretation.
5. If you experience resting heart rate below 50 bpm, significant chest discomfort, or severe cognitive impairment, contact your prescriber the same day rather than waiting for the scheduled lab visit.